Measles Clinical Trial
Official title:
An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months
Verified date | August 2018 |
Source | Merck Sharp & Dohme Corp. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary objective:
To demonstrate that two doses of ProQuad® administered by IM route are as immunogenic as two
doses of ProQuad® administered by SC route to healthy children 12 to 18 months of age in
terms of antibody response rates to measles, mumps, rubella and to varicella at 42 days
following the second dose of ProQuad®
Secondary objectives:
- To describe the antibody response rates to measles, mumps, rubella and varicella
measured 30 days following the first dose of ProQuad® administered by IM or SC route,
- To describe the antibody titres to measles, mumps, rubella and varicella at 30 days
following the first dose and at 42 days following the second dose of ProQuad® both
administered by IM or SC route,
- To describe the safety profile of two doses of ProQuad® both administered by IM or SC
route.
Status | Completed |
Enrollment | 405 |
Est. completion date | May 11, 2007 |
Est. primary completion date | May 11, 2007 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 18 Months |
Eligibility |
Inclusion Criteria: - Healthy participant of either gender, - Age 12 to 18 months, - Negative clinical history of measles, mumps, rubella, varicella and zoster, - Consent form signed by both holders of the parental authority or by the legal representative - Holder(s) of the the parental authority / legal representative able to understand the protocol requirements and to fill in the Diary Card. Exclusion Criteria: - Prior receipt of measles, mumps, rubella and/or varicella vaccine either alone or in any combination, - Any recent (=30 days) exposure to measles, mumps, rubella, varicella and/or zoster - Any recent (=3 days) history of febrile illness - Any severe chronic disease, - Active untreated tuberculosis, - Known personal history of seizure disorder, - Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems, - Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, - Any immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity including those resulting from corticosteroid [any long-term (=14 days) administration of systemic corticosteroid therapy given daily or on alternate days at high doses (=2 mg/kg/day prednisone equivalent or =20 mg/day if weight more than 10 kg) within the previous 30 days] or other immunosuppressive therapy, - Any previous (= 150 days) receipt of immune globulin or any blood-derived product or scheduled to be administered through Visit 3, - Any recent (=7 days) tuberculin test or scheduled tuberculin test through Visit 3, - Any recent (=30 days) receipt of an inactivated or a live vaccine or scheduled vaccination through Visit 3, |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Merck Sharp & Dohme Corp. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Meeting Antibody Response Rate Criteria Six Weeks After Completing ProQuad® Treatment | Antibody response rates were determined 6 weeks after the second dose of IM or SC ProQuad®. Measles, mumps and rubella antibody levels were determined using enzyme-linked immunosorbent assay (ELISA) and varicella antibody levels were determined with glycoprotein-based ELISA (gpELISA). Response rates were determined as follows: measles antibody titre =255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre =10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre =10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre =5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL. | Week 10 (6 weeks after Dose 2 on Week 4) | |
Secondary | Percentage of Participants Meeting Antibody Response Rate Criteria Four Weeks After the First ProQuad® Dose | Antibody response rates were determined 4 weeks after the first dose of IM or SC ProQuad®. Measles, mumps and rubella antibody levels were determined using ELISA and varicella antibody levels were determined with gpELISA. Response rates were determined as follows: measles antibody titre =255 mIU/mL in participants with baseline titre <255 mIU/mL; mumps antibody titre =10 ELISA Ab units/mL in participants with baseline titre <10 ELISA Ab units mL; rubella antibody titre =10 IU/mL in participants with baseline titre <10 IU/mL; varicella antibody titre =5 gpELISA units/mL in participants with baseline titre <1.25 gpELISA units/mL. | Week 4 | |
Secondary | Antibody Geometric Mean Titres (GMT) to Measles Four Weeks After the First ProQuad® Dose | Antibody titre levels to measles were determined 4 weeks after the first dose of IM or SC ProQuad®. Measles antibody levels were determined using ELISA. Titre levels were determined in participants with baseline measles titre <255 mIU/mL. | Week 4 | |
Secondary | Antibody GMT to Mumps Four Weeks After the First ProQuad® Dose | Antibody titre levels to mumps were determined 4 weeks after the first dose of IM or SC ProQuad®. Mumps antibody levels were determined using ELISA. Titre levels were determined in participants with baseline mumps titres <10 ELISA Ab units mL. | Week 4 | |
Secondary | Antibody GMT to Rubella Four Weeks After the First ProQuad® Dose | Antibody titre levels to rubella were determined 4 weeks after the first dose of IM or SC ProQuad®. Rubella antibody levels were determined using ELISA. Titre levels were determined in participants with baseline rubella titre <10 IU/mL. | Week 4 | |
Secondary | Antibody GMT to Varicella Four Weeks After the First ProQuad® Dose | Antibody titre levels to varicella were determined 4 weeks after the first dose of IM or SC ProQuad®. Varicella antibody levels were determined with gpELISA. Titre levels were determined in participants with baseline varicella antibody titre <1.25 gpELISA units/mL. | Week 4 | |
Secondary | Antibody GMT to Measles Six Weeks After Completing ProQuad® Treatment | Antibody titre levels to measles were determined 6 weeks after the second dose of IM or SC ProQuad®. Measles antibody levels were determined using ELISA. Titre levels were determined in participants with baseline measles titre <255 mIU/mL. | Week 10 (6 weeks after Dose 2 on Week 4) | |
Secondary | Antibody GMT to Mumps Six Weeks After Completing ProQuad® Treatment | Antibody titre levels to mumps were determined 6 weeks after the second dose of IM or SC ProQuad®. Mumps antibody levels were determined using ELISA. Titre levels were determined in participants with baseline mumps titre <10 ELISA Ab units mL. | Week 10 (6 weeks after Dose 2 on Week 4) | |
Secondary | Antibody GMT to Rubella Six Weeks After Completing ProQuad® Treatment | Antibody titre levels to rubella were determined 6 weeks after the second dose of IM or SC ProQuad®. Rubella antibody levels were determined using ELISA. Titre levels were determined in participants with baseline rubella titre <10 IU/mL. | Week 10 (6 weeks after Dose 2 on Week 4) | |
Secondary | Antibody GMT to Varicella Six Weeks After Completing ProQuad® Treatment | Antibody titre levels to varicella were determined 6 weeks after the second dose of IM or SC ProQuad®. Varicella antibody levels were determined with gpELISA. Titre levels were determined in participants with baseline varicella antibody titre <1.25 gpELISA units/mL. | Week 10 (6 weeks after Dose 2 on Week 4) | |
Secondary | Percentage of Participants Experiencing an Injection-site Adverse Event (AE) or Vaccine-related Systemic AE After the First ProQuad® Dose | An AE is any untoward medical occurrence in a participant administered an investigational medicinal product (IMP) and which does not necessarily have a causal relationship with the IMP. Injection-site AEs (e.g., erythema, swelling, pain) and systemic vaccine-related AEs (e.g., pyrexia) were AEs of interest. | From Day 0 up to Day 28 (up to 28 days after the first ProQuad® dose) | |
Secondary | Percentage of Participants Experiencing an Injection-site AE or Vaccine-related Systemic AE After the Second ProQuad® Dose | An AE is any untoward medical occurrence in a participant administered an IMP and which does not necessarily have a causal relationship with the IMP. Injection-site AEs (e.g., erythema, swelling, pain) and systemic vaccine-related AEs (e.g., pyrexia) were AEs of interest. | From Day 30 up to Day 58 (up to 28 days after the second ProQuad® dose) | |
Secondary | Percentage of Participants Discontinuing From Study Therapy Due to an AE After the First ProQuad® Dose | An AE is any untoward medical occurrence in a participant administered an IMP and which does not necessarily have a causal relationship with the IMP. | From Day 0 up to Day 28 (up to 28 days after the first ProQuad® dose) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04183114 -
Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
|
Phase 2/Phase 3 | |
Completed |
NCT00092430 -
Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
|
Phase 3 | |
Completed |
NCT02196285 -
Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
|
Phase 1 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00313950 -
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
|
Phase 4 | |
Completed |
NCT00560755 -
Safety Study of ProQuad® rHA in Infants (V221-037)
|
Phase 3 | |
Completed |
NCT01878435 -
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya
|
N/A | |
Completed |
NCT01777529 -
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
|
Phase 4 | |
Terminated |
NCT00258726 -
Immune Responses to Two Dose Varivax +/- MMR-II
|
Phase 1/Phase 2 | |
Completed |
NCT00109278 -
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
|
Phase 2 | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Completed |
NCT02880865 -
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
|
Phase 4 | |
Completed |
NCT01681992 -
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
|
Phase 3 | |
Completed |
NCT00751348 -
Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
|
Phase 3 | |
Completed |
NCT01702428 -
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
|
Phase 3 | |
Completed |
NCT00969436 -
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
|
Phase 3 | |
Completed |
NCT00566527 -
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
|
Phase 3 | |
Completed |
NCT00127010 -
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
|
Phase 3 | |
Completed |
NCT00388440 -
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
|
Phase 4 | |
Completed |
NCT03148990 -
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
|
Phase 2/Phase 3 |